Tricida to Present at the Needham Virtual Healthcare Conference
April 08 2021 - 12:15PM
Tricida, Inc. (Nasdaq: TCDA) today announced that it will
present at the 20th Annual Needham Virtual Healthcare Conference on
Tuesday, April 13, 2021 at 12:45 pm PT / 3:45 pm ET. Tricida will
provide a company overview, business update and progress on the
company’s key initiatives.
A live webcast of the presentation will be accessible on the
Tricida website at IR.Tricida.com. An archive of the webcast will
be available for 90 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the
development and commercialization of its investigational drug
candidate, veverimer, a non-absorbed, orally-administered polymer
designed to treat metabolic acidosis in patients with CKD. Tricida
is currently conducting a renal outcomes clinical trial, VALOR-CKD,
to determine if veverimer slows progression of CKD in patients with
metabolic acidosis and CKD. There are no FDA-approved treatments
for chronic metabolic acidosis, a condition commonly caused by CKD
that is believed to accelerate the progression of kidney
deterioration. It is estimated to pose a health risk to
approximately three million patients with CKD in the United
States.
For more information about Tricida, please
visit www.tricida.com.
Contact:
Jackie Cossmon, IRCTricida, Inc.Senior Vice President of
Investor Relations and CommunicationsIR@Tricida.com
Tricida (NASDAQ:TCDA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Tricida (NASDAQ:TCDA)
Historical Stock Chart
From Mar 2023 to Mar 2024